Factors influencing survival after relapse from acute lymphoblastic leukemia

A Children's Oncology Group study

K. Nguyen, M. Devidas, S. C. Cheng, M. La, E. A. Raetz, W. L. Carroll, N. J. Winick, S. P. Hunger, P. S. Gaynon, M. L. Loh

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Despite great progress in curing childhood acute lymphoblastic leukemia (ALL), survival after relapse remains poor. We analyzed survival after relapse among 9585 pediatric patients enrolled on Children's Oncology Group clinical trials between 1988 and 2002. A total of 1961 patients (20.5%) experienced relapse at any site. The primary end point was survival. Patients were subcategorized by the site of relapse and timing of relapse from initial diagnosis. Time to relapse remains the strongest predictor of survival. Patients experiencing early relapse less than 18 months from initial diagnosis had a particularly poor outcome with a 5-year survival estimate of 21.0±1.8%. Standard risk patients who relapsed had improved survival compared with their higher risk counterparts; differences in survival for the two risk groups was most pronounced for patients relapsing after 18 months. Adjusting for both time and relapse site, multivariate analysis showed that age (10+ years) and the presence of central nervous system disease at diagnosis, male gender, and T-cell disease were significant predictors of inferior post-relapse survival. It can be noted that there was no difference in survival rates for relapsed patients in earlier vs later era trials. New therapeutic strategies are urgently needed for children with relapsed ALL and efforts should focus on discovering the biological pathways that mediate drug resistance.

Original languageEnglish (US)
Pages (from-to)2142-2150
Number of pages9
JournalLeukemia
Volume22
Issue number12
DOIs
StatePublished - 2008

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Survival
Central Nervous System Diseases
Drug Resistance
Multivariate Analysis
Survival Rate
Clinical Trials
Pediatrics
T-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Nguyen, K., Devidas, M., Cheng, S. C., La, M., Raetz, E. A., Carroll, W. L., ... Loh, M. L. (2008). Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children's Oncology Group study. Leukemia, 22(12), 2142-2150. https://doi.org/10.1038/leu.2008.251

Factors influencing survival after relapse from acute lymphoblastic leukemia : A Children's Oncology Group study. / Nguyen, K.; Devidas, M.; Cheng, S. C.; La, M.; Raetz, E. A.; Carroll, W. L.; Winick, N. J.; Hunger, S. P.; Gaynon, P. S.; Loh, M. L.

In: Leukemia, Vol. 22, No. 12, 2008, p. 2142-2150.

Research output: Contribution to journalArticle

Nguyen, K, Devidas, M, Cheng, SC, La, M, Raetz, EA, Carroll, WL, Winick, NJ, Hunger, SP, Gaynon, PS & Loh, ML 2008, 'Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children's Oncology Group study', Leukemia, vol. 22, no. 12, pp. 2142-2150. https://doi.org/10.1038/leu.2008.251
Nguyen, K. ; Devidas, M. ; Cheng, S. C. ; La, M. ; Raetz, E. A. ; Carroll, W. L. ; Winick, N. J. ; Hunger, S. P. ; Gaynon, P. S. ; Loh, M. L. / Factors influencing survival after relapse from acute lymphoblastic leukemia : A Children's Oncology Group study. In: Leukemia. 2008 ; Vol. 22, No. 12. pp. 2142-2150.
@article{9381e056536049eba6513fa6abdccb34,
title = "Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children's Oncology Group study",
abstract = "Despite great progress in curing childhood acute lymphoblastic leukemia (ALL), survival after relapse remains poor. We analyzed survival after relapse among 9585 pediatric patients enrolled on Children's Oncology Group clinical trials between 1988 and 2002. A total of 1961 patients (20.5{\%}) experienced relapse at any site. The primary end point was survival. Patients were subcategorized by the site of relapse and timing of relapse from initial diagnosis. Time to relapse remains the strongest predictor of survival. Patients experiencing early relapse less than 18 months from initial diagnosis had a particularly poor outcome with a 5-year survival estimate of 21.0±1.8{\%}. Standard risk patients who relapsed had improved survival compared with their higher risk counterparts; differences in survival for the two risk groups was most pronounced for patients relapsing after 18 months. Adjusting for both time and relapse site, multivariate analysis showed that age (10+ years) and the presence of central nervous system disease at diagnosis, male gender, and T-cell disease were significant predictors of inferior post-relapse survival. It can be noted that there was no difference in survival rates for relapsed patients in earlier vs later era trials. New therapeutic strategies are urgently needed for children with relapsed ALL and efforts should focus on discovering the biological pathways that mediate drug resistance.",
author = "K. Nguyen and M. Devidas and Cheng, {S. C.} and M. La and Raetz, {E. A.} and Carroll, {W. L.} and Winick, {N. J.} and Hunger, {S. P.} and Gaynon, {P. S.} and Loh, {M. L.}",
year = "2008",
doi = "10.1038/leu.2008.251",
language = "English (US)",
volume = "22",
pages = "2142--2150",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Factors influencing survival after relapse from acute lymphoblastic leukemia

T2 - A Children's Oncology Group study

AU - Nguyen, K.

AU - Devidas, M.

AU - Cheng, S. C.

AU - La, M.

AU - Raetz, E. A.

AU - Carroll, W. L.

AU - Winick, N. J.

AU - Hunger, S. P.

AU - Gaynon, P. S.

AU - Loh, M. L.

PY - 2008

Y1 - 2008

N2 - Despite great progress in curing childhood acute lymphoblastic leukemia (ALL), survival after relapse remains poor. We analyzed survival after relapse among 9585 pediatric patients enrolled on Children's Oncology Group clinical trials between 1988 and 2002. A total of 1961 patients (20.5%) experienced relapse at any site. The primary end point was survival. Patients were subcategorized by the site of relapse and timing of relapse from initial diagnosis. Time to relapse remains the strongest predictor of survival. Patients experiencing early relapse less than 18 months from initial diagnosis had a particularly poor outcome with a 5-year survival estimate of 21.0±1.8%. Standard risk patients who relapsed had improved survival compared with their higher risk counterparts; differences in survival for the two risk groups was most pronounced for patients relapsing after 18 months. Adjusting for both time and relapse site, multivariate analysis showed that age (10+ years) and the presence of central nervous system disease at diagnosis, male gender, and T-cell disease were significant predictors of inferior post-relapse survival. It can be noted that there was no difference in survival rates for relapsed patients in earlier vs later era trials. New therapeutic strategies are urgently needed for children with relapsed ALL and efforts should focus on discovering the biological pathways that mediate drug resistance.

AB - Despite great progress in curing childhood acute lymphoblastic leukemia (ALL), survival after relapse remains poor. We analyzed survival after relapse among 9585 pediatric patients enrolled on Children's Oncology Group clinical trials between 1988 and 2002. A total of 1961 patients (20.5%) experienced relapse at any site. The primary end point was survival. Patients were subcategorized by the site of relapse and timing of relapse from initial diagnosis. Time to relapse remains the strongest predictor of survival. Patients experiencing early relapse less than 18 months from initial diagnosis had a particularly poor outcome with a 5-year survival estimate of 21.0±1.8%. Standard risk patients who relapsed had improved survival compared with their higher risk counterparts; differences in survival for the two risk groups was most pronounced for patients relapsing after 18 months. Adjusting for both time and relapse site, multivariate analysis showed that age (10+ years) and the presence of central nervous system disease at diagnosis, male gender, and T-cell disease were significant predictors of inferior post-relapse survival. It can be noted that there was no difference in survival rates for relapsed patients in earlier vs later era trials. New therapeutic strategies are urgently needed for children with relapsed ALL and efforts should focus on discovering the biological pathways that mediate drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=57849138262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849138262&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.251

DO - 10.1038/leu.2008.251

M3 - Article

VL - 22

SP - 2142

EP - 2150

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -